Controversia en el uso y en la financiación de SYSADOA para la osteoartritis en España: un análisis del debate científico-social en los medios de comunicación

IF 1.3 Q4 RHEUMATOLOGY Reumatologia Clinica Pub Date : 2024-10-01 Epub Date: 2024-07-14 DOI:10.1016/j.reuma.2024.05.002

Pedro Alfonso Domínguez Vera , Luis Carrasco Páez

{"title":"Controversia en el uso y en la financiación de SYSADOA para la osteoartritis en España: un análisis del debate científico-social en los medios de comunicación","authors":"Pedro Alfonso Domínguez Vera , Luis Carrasco Páez","doi":"10.1016/j.reuma.2024.05.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and objective</h3><div>The use of SYmptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) in the treatment of osteoarthritis (OA) has been a topic of debate in the scientific community and public entities regarding their public financing in Spain. The objective of this study was to describe and analyze the main positions of media outlets, public entities, regarding the use and financing of SYSADOA in Spain.</div></div><div><h3>Methods</h3><div>A qualitative and quantitative analysis of the content regarding the use and financing of SYSADOA was conducted in general media outlets (<em>El País</em>, <em>El Mundo, La Vanguardia, ABC,</em> and <em>20minutos</em>), public statements, and Twitter® publications.</div></div><div><h3>Results</h3><div>A total of 15 articles in general media outlets, 872 tweets, and 7 public entity statements were identified. Mostly, media outlets (91%) and social media platforms (78%) exhibited a favorable trend towards funding.</div></div><div><h3>Discussion and conclusions</h3><div>The use of SYSADOA in OA patients continues to be controversial in the scientific community. However, there is consensus among patient associations in favor of public funding and use as a treatment for OA patients.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 8","pages":"Pages 416-422"},"PeriodicalIF":1.3000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reumatologia Clinica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1699258X24000494","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/14 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective

The use of SYmptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) in the treatment of osteoarthritis (OA) has been a topic of debate in the scientific community and public entities regarding their public financing in Spain. The objective of this study was to describe and analyze the main positions of media outlets, public entities, regarding the use and financing of SYSADOA in Spain.

Methods

A qualitative and quantitative analysis of the content regarding the use and financing of SYSADOA was conducted in general media outlets (El País, El Mundo, La Vanguardia, ABC, and 20minutos), public statements, and Twitter® publications.

Results

A total of 15 articles in general media outlets, 872 tweets, and 7 public entity statements were identified. Mostly, media outlets (91%) and social media platforms (78%) exhibited a favorable trend towards funding.

Discussion and conclusions

The use of SYSADOA in OA patients continues to be controversial in the scientific community. However, there is consensus among patient associations in favor of public funding and use as a treatment for OA patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

西班牙骨关节炎使用和资助 SYSADOA 的争议：媒体社会科学辩论分析

背景和目的在西班牙，骨关节炎慢作用药物 SYSADOA（SYmptomatic Slow-Acting Drugs for Osteoarthritis）在治疗骨关节炎（OA）方面的应用一直是科学界和公共实体就其公共融资问题争论不休的话题。本研究旨在描述和分析媒体、公共实体对西班牙使用和资助 SYSADOA 的主要立场。研究方法对一般媒体（El País、El Mundo、La Vanguardia、ABC 和 20minutos）、公共声明和 Twitter® 出版物中有关 SYSADOA 使用和资助的内容进行了定性和定量分析。结果共发现 15 篇一般媒体文章、872 条微博和 7 份公共实体声明。大多数媒体（91%）和社交媒体平台（78%）对资助表现出了积极的趋势。讨论与结论在 OA 患者中使用 SYSADOA 在科学界仍存在争议。然而，患者协会已达成共识，赞成公共资助并将其用作治疗 OA 患者的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Reumatologia Clinica RHEUMATOLOGY-

CiteScore

2.40

自引率

6.70%

发文量

105

审稿时长

54 days

期刊介绍： Una gran revista para cubrir eficazmente las necesidades de conocimientos en una patología de etiología, expresividad clínica y tratamiento tan amplios. Además es La Publicación Oficial de la Sociedad Española de Reumatología y del Colegio Mexicano de Reumatología y está incluida en los más prestigiosos índices de referencia en medicina.